⏳ Fetching live dividend data...
Home › Calculator › ADOIF Dividend Calculator 2026
Adocia S.A. · OTC
Price: $8.87 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ADOIF → $2087948.47M in 10 years · $173,245,286,374.70/month
Adocia S.A., a biotechnology firm founded in Lyon, France, in 2005, operates at the clinical stage, focusing its research and development efforts on optimizing existing therapeutic proteins and peptides for the management of diabetes and various other metabolic conditions. The company's core innovation lies in its proprietary BioChaperone technological platform, specifically engineered to enhance the effectiveness and performance of therapeutic proteins. Adocia's product pipeline currently in clinical trials features several advanced insulin formulations. These include BioChaperone Lispro U100 and U200, which offer ultra-rapid action derived from rapid insulin lispro. Other notable candidates are BioChaperone Combo, a combination of both long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; BioChaperone Glucagon, an aqueous human glucagon formulation for treating low blood sugar; and M1Pram, a product based on a metabolite of insulin glargine and pramlintide. In addition to its clinical assets, Adocia boasts a strong preclinical pipeline. This includes bi-hormonal treatments such as BioChaperone AsPram, which combines rapid insulin aspart with pramlintide, and BioChaperone Glargine Liraglutidea, a fixed-dose combination of insulin glargine with a GLP-1 receptor analogue. The company is also exploring multihormonal solutions for obesity, including BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a triple therapy comprising pramlintide, glucagon, and exenatide. Globally, Adocia has established a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. This collaboration aims to develop and bring to market BioChaperone Lispro and BioChaperone Combo throughout China, as well as in other regions across Asia and the Middle East.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ADOIF position with:
Real after-tax yield depends on where you live and how you hold ADOIF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 22.55% | 19.75% | $2,255 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 19.17% | 16.37% | $1,917 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 18.04% | 15.24% | $1,804 / yr |
| 🇬🇧 UK ISA | 0% | 22.55% | 19.75% | $2,255 / yr |
| 🇬🇧 UK Taxable | 8.75% | 20.58% | 17.78% | $2,058 / yr |
| 🇨🇦 TFSA | 0% | 22.55% | 19.75% | $2,255 / yr |
| 🇨🇦 CA Taxable | 25% | 16.91% | 14.11% | $1,691 / yr |
| 🇦🇺 Super (pension) | 15% | 19.17% | 16.37% | $1,917 / yr |
| 🇦🇺 AU Taxable | 30% | 15.79% | 12.98% | $1,579 / yr |
| 🇩🇪 DE Taxable | 26.375% | 16.60% | 13.80% | $1,660 / yr |
| 🇫🇷 FR Taxable | 30% | 15.79% | 12.98% | $1,579 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ADOIF pays quarterly — 4 times per year. Next ex-div: TBD.
How ADOIF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ADOIF sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ADOIF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Adocia S.A. (ADOIF) is currently trading at $8.87, trading near its 52-week low. The current dividend yield is 22.55% based on an annual payout of $2.00 per share.
Adocia S.A. (ADOIF) is a healthcare stock currently trading at $8.87 with a dividend yield of 22.55%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever